Skip to main content
. 2018 May 9;42(2):851–860. doi: 10.3892/ijmm.2018.3662

Figure 2.

Figure 2

TGF-β/Smad3 pathway involved in EMT to HLE-B3 cells challenged with TGF-β2 (10 ng/ml). (A) Gene expression of EMT biomarkers inhibited by SIS3 in HLE-B3 cells. (B) Protein expression of EMT markers in HLE-B3 cells challenged with TGF-β2 (10 ng/ml) following treatment with Smad3 inhibitor SIS3. Scale bar=100 µm. *P<0.05 TGF-β2 + SIS3 group vs. the corresponding TGF-β2 group. TGF-β, transforming growth factor-β; Smad3, mothers against decapentaplegic 3; EMT, epithelial-mesenchymal transition; α-SMA, α-smooth muscle actin; FN1, fibronectin 1; COL1A1, collagen type 1 α1; CDH1, E-cadherin.